We are live on ! Find out more
Marshall Wace

Marshall Wace Portfolio holdings

AUM $127B Turnover 40.17%
1-Year Est. Return 46.06%
This Fund
S&P 500
This Quarter Est. Return
+26.15%
1 Year Est. Return
+46.06%
3 Year Est. Return
+142.12%
5 Year Est. Return
+190.33%
10 Year Est. Return
+787.47%
AUM
$127B
AUM Growth
+$26.3B
Cap. Flow
+$9.28B
Cap. Flow %
7.32%
Top 10 Hldgs %
37.66%
Holding
3,898
New
771
Increased
1,083
Reduced
1,182
Closed
795
Avg Time Held Equity + Options
1 year
Top 10 Avg Time Held Equity + Options
2.3 years
Top 20 Avg Time Held Equity + Options
1.6 years
Avg Time Held Equity only
1 year
Top 10 Avg Time Held Equity only
2.4 years
Top 20 Avg Time Held Equity only
1.6 years

Top Buys

Rank Stock Value
1
IVV icon
iShares Core S&P 500 ETF
IVV
+$9.9B
2
COST icon
Costco
COST
+$907M
3
ABBV icon
AbbVie
ABBV
+$643M
4
JPM icon
JPMorgan Chase
JPM
+$609M
5
BAC icon
Bank of America
BAC
+$567M

Top Sells

Rank Stock Value
1
NVDA icon
NVIDIA
NVDA
+$1.03B
2
MELI icon
Mercado Libre
MELI
+$528M
3
AVGO icon
Broadcom
AVGO
+$514M
4
SNDK icon
Sandisk
SNDK
+$507M
5
MRVL icon
Marvell Technology
MRVL
+$499M

Sector Composition

Rank Sector Weight
1 Miscellaneous 34.91%
2 Technology 20.64%
3 Consumer Discretionary 9.1%
4 Healthcare 8.21%
5 Financials 7.4%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake
Capital Flow Held Since
EA icon
401
DELISTED
Electronic Arts
EA
$46M 0.04%
224,550
+104
+0% +$21.1K
2024 Q3
7 quarters
CRWV icon
402
PUT
CoreWeave
CRWV
$29.9B
$46M 0.04%
+462,000
New +$49.9M
2026 Q2
0 quarters
CVCO icon
403
Cavco Industries
CVCO
$4.11B
$46M 0.04%
74,839
+67,999
+994% +$36.1M
2025 Q4
2 quarters
PRAX icon
404
Praxis Precision Medicines
PRAX
$7.06B
$45.9M 0.04%
137,008
+91,859
+203% +$29.1M
2025 Q3
3 quarters
ADSK icon
405
Autodesk
ADSK
$52.7B
$45.8M 0.04%
235,800
-10,529
-4% -$2.4M
2022 Q3
15 quarters
RVMD icon
406
Revolution Medicines
RVMD
$40.1B
$45.8M 0.04%
244,544
+27,883
+13% +$4.07M
2023 Q3
11 quarters
TMO icon
407
PUT
Thermo Fisher Scientific
TMO
$249B
$45.7M 0.04%
91,200
+90,500
+12,929% +$43.4M
2026 Q1
1 quarter
GFL icon
408
GFL Environmental
GFL
$19.9B
$45.7M 0.04%
1,242,546
-914,298
-42% -$34.6M
2023 Q1
13 quarters
NBIX icon
409
Neurocrine Biosciences
NBIX
$14.5B
$45.6M 0.04%
270,754
-238,223
-47% -$35.3M
2025 Q2
4 quarters
CI icon
410
Cigna
CI
$81.1B
$45.6M 0.04%
165,287
+108,107
+189% +$30.5M
2025 Q2
4 quarters
EXEL icon
411
Exelixis
EXEL
$16B
$45.2M 0.04%
831,506
+531,493
+177% +$25.9M
2026 Q1
1 quarter
SPGI icon
412
S&P Global
SPGI
$133B
$44.7M 0.04%
109,730
+87,647
+397% +$37M
2016 Q2
40 quarters
MOD icon
413
Modine Manufacturing
MOD
$7.09B
$44.7M 0.04%
167,285
+92,127
+123% +$24.3M
2024 Q2
8 quarters
ACAD icon
414
Acadia Pharmaceuticals
ACAD
$3.4B
$44.7M 0.04%
1,764,838
+1,688,651
+2,216% +$37.2M
2024 Q1
9 quarters
KVUE icon
415
Kenvue
KVUE
$37.6B
$44.5M 0.04%
2,328,167
-11,820,394
-84% -$208M
2023 Q2
12 quarters
MTDR icon
416
Matador Resources
MTDR
$7.42B
$44.4M 0.04%
891,834
+766,253
+610% +$43.6M
2026 Q1
1 quarter
FIGS icon
417
FIGS
FIGS
$3.36B
$44.4M 0.04%
4,335,698
+1,119,236
+35% +$14.7M
2023 Q1
13 quarters
HWM icon
418
Howmet Aerospace
HWM
$74.1B
$44.3M 0.04%
164,754
-130,636
-44% -$33.5M
2025 Q4
2 quarters
SLV icon
419
iShares Silver Trust
SLV
$26.2B
$44.1M 0.03%
825,075
+430,398
+109% +$28.5M
2024 Q3
7 quarters
GKOS icon
420
Glaukos
GKOS
$10.6B
$44M 0.03%
314,804
+280,705
+823% +$35.5M
2025 Q1
5 quarters
ISRG icon
421
Intuitive Surgical
ISRG
$160B
$43.8M 0.03%
110,089
-209,908
-66% -$91.7M
2020 Q2
24 quarters
FOX icon
422
Fox Class B
FOX
$25.1B
$43.7M 0.03%
933,541
+913,641
+4,591% +$50.8M
2024 Q3
7 quarters
RVLV icon
423
Revolve Group
RVLV
$1.58B
$43.6M 0.03%
1,904,833
-45,918
-2% -$1.02M
2024 Q1
9 quarters
LULU icon
424
lululemon athletica
LULU
$11.5B
$43.4M 0.03%
380,476
-677,172
-64% -$90.5M
2025 Q2
4 quarters
FUTU icon
425
Futu Holdings
FUTU
$13.9B
$43.2M 0.03%
460,493
-151,370
-25% -$19.4M
2023 Q2
12 quarters

Similar funds

Marshall Wace's Q2 2026 Portfolio in Review

As of Q2 2026, Marshall Wace held 3,898 positions worth $127B, up 26% from $100B the previous quarter. Its ten largest holdings account for 38% of the portfolio.

Marshall Wace deployed $9.28B of net new capital in Q2 2026, opening 771 new positions and adding to 1,083 existing holdings. Its largest new stake was LPL Financial: 975,627 shares worth $275M.

By sector, the portfolio is most concentrated in Miscellaneous at 35% of assets, up from 30% a quarter earlier, followed by Technology and Consumer Discretionary.

On the sell side, the largest reduction was NVIDIA, an estimated $1.03B trimmed.

  • Marshall Wace's largest Q2 2026 buy was LPL Financial: 975,627 shares worth $275M.
  • Marshall Wace added most to iShares Core S&P 500 ETF in Q2 2026, an estimated $9.9B increase.
  • Marshall Wace's biggest Q2 2026 reduction was NVIDIA, cutting an estimated $1.03B.
  • Marshall Wace fully exited Merck in Q2 2026, selling an estimated $325M.
  • Marshall Wace's ten largest holdings make up 38% of its $127B portfolio in Q2 2026.
  • Marshall Wace opened 771 new positions and closed 795 in Q2 2026.
  • Marshall Wace's portfolio value rose 26% quarter-over-quarter to $127B.

Based on Marshall Wace's 13F filing for Q2 2026, filed 13 Aug 2026.